FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385698511> ?p ?o ?g. }

• W4385698511 endingPage "4032" @default.
• W4385698511 startingPage "4032" @default.
• W4385698511 abstract "The programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway plays a crucial role in the immune escape mechanism and growth of cancer cells in endometrial cancer (EC). Clinical trials investigating PD-1/PD-L1 inhibitor have shown promising results in other cancers, but their efficacy in EC still remains uncertain. Therefore, this meta-analysis aims to provide an updated and robust analysis of the effectiveness and safety of PD-1/PDL1 inhibitor as single-agent immunotherapy in EC, focusing on the objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). This meta-analysis utilized STATA version 17 and RevMan version 5.4 software to pool the results of relevant studies. Five studies conducted between 2017 and 2022, comprising a total of 480 EC patients enrolled for PD-1/PD-L1 inhibitor immunotherapy met the inclusion criteria. The pooled proportion of EC patients who achieved ORR through PD-1/PD-L1 inhibitor treatment was 26.0% (95% CI: 16.0–36.0%; p < 0.05). Subgroup analysis based on mismatch repair (MMR) status showed an ORR of 44.0% (95% CI: 38.0–50.0%; p = 0.32) for the deficient mismatch repair (dMMR) group and 8.0% (95% CI: 0.0–16.0%; p = 0.07) for the proficient mismatch repair (pMMR) group. Pooled proportion analysis by DCR demonstrated an odds ratio (OR) of 41.0% (95% CI: 36.0–46.0%, p = 0.83) for patients undergoing PD-1/PD-L1 inhibitor treatment. Subgroup analysis based on MMR status revealed DCR of 54.0% (95% CI: 47.0–62.0%; p = 0.83) for the dMMR group, and 31.0% (95% CI: 25.0–39.0%; p = 0.14) for the pMMR group. The efficacy of PD-1/PD-L1 inhibitors was significantly higher in the dMMR group compared to the pMMR group, in terms of both ORR (OR = 6.30; 95% CI = 3.60–11.03; p < 0.05) and DCR (OR = 2.57; 95% CI = 1.66–3.99; p < 0.05). In terms of safety issues, the pooled proportion of patients experiencing at least one adverse event was 69.0% (95% CI: 65.0–73.0%; p > 0.05), with grade three or higher AEs occurring in 16.0% of cases (95% CI: 12.0–19.0%; p > 0.05). Based on the subgroup analysis of MMR status, PD-1/PD-L1 inhibitor immunotherapy showed significantly better efficacy among dMMR patients. These findings suggest that patients with dMMR status may be more suitable for this treatment approach. However, further research on PD-1/PD-L1 inhibitor immunotherapy strategies is needed to fully explore their potential and improve treatment outcomes in EC." @default.
• W4385698511 created "2023-08-10" @default.
• W4385698511 creator A5006465517 @default.
• W4385698511 creator A5029657020 @default.
• W4385698511 creator A5039296343 @default.
• W4385698511 creator A5047559688 @default.
• W4385698511 creator A5054280394 @default.
• W4385698511 creator A5056324963 @default.
• W4385698511 creator A5092618390 @default.
• W4385698511 creator A5092618391 @default.
• W4385698511 date "2023-08-09" @default.
• W4385698511 modified "2023-10-14" @default.
• W4385698511 title "Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis" @default.
• W4385698511 cites W1966756094 @default.
• W4385698511 cites W2041440766 @default.
• W4385698511 cites W2044835625 @default.
• W4385698511 cites W2074146123 @default.
• W4385698511 cites W2116475791 @default.
• W4385698511 cites W2156098321 @default.
• W4385698511 cites W2199384387 @default.
• W4385698511 cites W2291203170 @default.
• W4385698511 cites W2570729870 @default.
• W4385698511 cites W2612419201 @default.
• W4385698511 cites W2620771841 @default.
• W4385698511 cites W2724136428 @default.
• W4385698511 cites W2743642528 @default.
• W4385698511 cites W2756648224 @default.
• W4385698511 cites W2777880635 @default.
• W4385698511 cites W2783137027 @default.
• W4385698511 cites W2783856064 @default.
• W4385698511 cites W2794612508 @default.
• W4385698511 cites W2810896552 @default.
• W4385698511 cites W2894234470 @default.
• W4385698511 cites W2914335731 @default.
• W4385698511 cites W2940759533 @default.
• W4385698511 cites W2947159010 @default.
• W4385698511 cites W2970410478 @default.
• W4385698511 cites W2991792334 @default.
• W4385698511 cites W3118615836 @default.
• W4385698511 cites W3157645496 @default.
• W4385698511 cites W3160246545 @default.
• W4385698511 cites W3166717456 @default.
• W4385698511 cites W3167167915 @default.
• W4385698511 cites W3172482128 @default.
• W4385698511 cites W3174259825 @default.
• W4385698511 cites W4200606903 @default.
• W4385698511 cites W4206041598 @default.
• W4385698511 cites W4206897023 @default.
• W4385698511 cites W4206901134 @default.
• W4385698511 cites W4210403377 @default.
• W4385698511 cites W4213121772 @default.
• W4385698511 cites W4226329559 @default.
• W4385698511 cites W4283359504 @default.
• W4385698511 cites W4284690625 @default.
• W4385698511 cites W4291366447 @default.
• W4385698511 cites W4296312326 @default.
• W4385698511 cites W4296373959 @default.
• W4385698511 cites W4312123989 @default.
• W4385698511 cites W4320918557 @default.
• W4385698511 cites W4323668949 @default.
• W4385698511 doi "https://doi.org/10.3390/cancers15164032" @default.
• W4385698511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37627060" @default.
• W4385698511 hasPublicationYear "2023" @default.
• W4385698511 type Work @default.
• W4385698511 citedByCount "0" @default.
• W4385698511 crossrefType "journal-article" @default.
• W4385698511 hasAuthorship W4385698511A5006465517 @default.
• W4385698511 hasAuthorship W4385698511A5029657020 @default.
• W4385698511 hasAuthorship W4385698511A5039296343 @default.
• W4385698511 hasAuthorship W4385698511A5047559688 @default.
• W4385698511 hasAuthorship W4385698511A5054280394 @default.
• W4385698511 hasAuthorship W4385698511A5056324963 @default.
• W4385698511 hasAuthorship W4385698511A5092618390 @default.
• W4385698511 hasAuthorship W4385698511A5092618391 @default.
• W4385698511 hasBestOaLocation W43856985111 @default.
• W4385698511 hasConcept C121608353 @default.
• W4385698511 hasConcept C126322002 @default.
• W4385698511 hasConcept C143998085 @default.
• W4385698511 hasConcept C156957248 @default.
• W4385698511 hasConcept C187960798 @default.
• W4385698511 hasConcept C197934379 @default.
• W4385698511 hasConcept C207103383 @default.
• W4385698511 hasConcept C2777088508 @default.
• W4385698511 hasConcept C2777701055 @default.
• W4385698511 hasConcept C2781053074 @default.
• W4385698511 hasConcept C44249647 @default.
• W4385698511 hasConcept C71924100 @default.
• W4385698511 hasConcept C90924648 @default.
• W4385698511 hasConcept C95190672 @default.
• W4385698511 hasConceptScore W4385698511C121608353 @default.
• W4385698511 hasConceptScore W4385698511C126322002 @default.
• W4385698511 hasConceptScore W4385698511C143998085 @default.
• W4385698511 hasConceptScore W4385698511C156957248 @default.
• W4385698511 hasConceptScore W4385698511C187960798 @default.
• W4385698511 hasConceptScore W4385698511C197934379 @default.
• W4385698511 hasConceptScore W4385698511C207103383 @default.
• W4385698511 hasConceptScore W4385698511C2777088508 @default.
• W4385698511 hasConceptScore W4385698511C2777701055 @default.

• next